Solana's market value is about $59.8 billion, roughly 15.3 times Sui's $3.9 billion. Both are high-speed layer 1 blockchains, and the market ranks Solana seventh by market cap versus Sui at 30th. Sui rose 25.7% over 60 days while SOL rose 5.8%, but Sui then fell 15.5% over 14 days to around $0.95. On a fully diluted basis, which counts all possible tokens, the gap narrows to about 6.8 times ($64.4 billion versus $9.5 billion), since only 41.2% of Sui's maximum 10 billion supply is circulating versus 92.7% of Solana's. U.S. spot Solana ETFs held about $1.61 billion in net assets as of October 22, 2026, though inflows have reversed from a peak, while the 21Shares Sui Staking ETF began trading on February 24, 2026, and SUI has dropped 32.1% in 2026.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
Open a keyword to see other news on the same topic.
Related tickers and likely impact
SOL/USDT
• NeutralSolana
Relevance: low
| Market | Crypto |
|---|---|
| Exchange | Binance |
| Sector | Layer 1 |
| Market cap | $61.0B |
| Close on 10/23/2026 | 102.85 |
| Change that session | -0.77% |
SUI/USDT
• NeutralSui
Relevance: low
| Market | Crypto |
|---|---|
| Exchange | Binance |
| Sector | Layer 1 |
| Market cap | $4.0B |
| Close on 10/23/2026 | 0.96080 |
| Change that session | -1.19% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Is Solana a Good Investment After a 65% Drop From Its Record High?
Solana (SOL) trades 65.4% below its record high of $293 and around $101, so it would need about a 189% gain to return to that peak. At $293, its market cap would need to be about $173 billion, compared with roughly $59.8 billion now, and ongoing staking rewards keep increasing supply. Alpenglow reduced transaction finality from around 12.8 seconds to 150 milliseconds, and J.P. Morgan Asset Management launched two funds on Solana, yet Solana ETFs saw $17.3 million in net outflows between October 19 and 22. SOL fell 47.2% over the past year, versus a 27.4% drop in Bitcoin, and the article considers a return to $293 before the end of 2027 unlikely. Conditions cited for improvement include Solana ETFs shifting from outflows to consistent inflows.
- Solana Is Faster and Cheaper Than Ethereum. So Why Is ETH Worth 5 Times More?
The article notes that Solana confirms transactions in 150 milliseconds at lower fees than Ethereum, yet Ethereum's $293.5 billion market cap is about 4.8 times Solana's $61.7 billion as of October 22, 2026. Investors favor ETH as a foundation for institutions and tokenized assets, while SOL draws interest mainly for speed and memecoin trading. Ethereum's 30-day chain revenue of $6.3 million is less than 2x Solana's $3.4 million, so the market-value gap suggests speculation plays a large role. U.S. spot Ether ETFs hold $15.4 billion, 9 times the $1.7 billion in Solana ETFs, indicating institutional investors favor Ethereum even more than the broader market.
- How a16z-backed DATA is rethinking its blockchain strategy after $30 million Sui deal
DATA, the a16z crypto-backed startup formerly known as Story Protocol, is shutting down its blockchain and moving to Sui after a $30 million investment from the Sui Foundation. The company had raised $140 million and built its own chain, but found changing how intellectual property is licensed harder than expected, so it narrowed its focus to AI training data. Its core product, Trace, is a registry that records the origin, consent terms and licensing history of training data, and partner Kled adds between 3 million and 4 million contributions a day. CEO Andrea Muttoni said the current goal is to provide a verifiable record for buyers and sellers rather than compete with data marketplaces, though DATA has not disclosed how many records have generated licensing revenue.
- Top Blockchains Continue to See Rapid Growth in AI Agent Payments. This Is the 1 Crypto You Need to Buy Right Now.
Chainalysis reported 138.5 million payments on Base using x402, a payment protocol built for AI agents, up from 58,800 transactions as of Q3 2025. Over 87% of x402 transactions were between $0.0001 and $0.10, sizes too small for traditional networks like Visa and Mastercard because of fees and chargeback risk. Solana ranks second in x402 volume, has overtaken Base in daily activity at several points this year, and launched batch settlement, which BlockRunAI says saves more than $20,000 a month in fees. However, TRM Labs counted $52.7 million across 198.9 million settlements since March 2025, with about $25.6 million plausible after removing suspicious activity, so agent payments are not yet driving much economic activity. Solana's stablecoin supply hit a record $17.3 billion in September, and the token trades about 64% below its January 2025 high of $293.
- Better Buy: Solana vs. XRP
The article compares XRP and Solana, two cryptocurrencies running on high-throughput blockchains after a recent rebound. XRP, the fifth-largest cryptocurrency with a market cap of nearly $82 billion, is tied to Ripple's activity and its RLUSD stablecoin, and is said to natively scale to 1,500 TPS, though critics question its decentralization. Solana, the seventh-largest with a $61 billion market cap, is described as the fastest major blockchain, surpassing 100,000 TPS in a network stress test, and has over $16 billion in circulating stablecoin supply. The author does not consider either a poor investment, but gives Solana the edge for its greater network activity, higher TPS and stronger stablecoin position.
- JPMorgan Solana Push Brings MONY and JLTXX Into Tokenized Finance
JPMorgan Asset Management is bringing two tokenized money market funds, MONY and JLTXX, to the Solana blockchain, giving qualified U.S. investors access through the Morgan Money platform. MONY, launched in December 2025, is a private placement offering, while JLTXX is a U.S.-registered government money market fund designed to support stablecoin issuers under the GENIUS Act. Both funds initially ran on Ethereum, and the expansion does not make them available to all retail investors. The article says the move strengthens Solana's position in institutional finance, though demand for SOL will depend on how much activity the products generate. With SOL trading around $103, the author's three-month base-case target is $122.58, while a more bullish scenario, in line with Standard Chartered's forecast, puts SOL at $250 by year-end.
Related markets
Latest news
- Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
Exelixis shares have risen 49% this year, but the FDA has extended the review of zanzalintinib, its investigational colorectal cancer drug, with a decision now expected by March 3, 2027, instead of December 3, 2026. The article argues the outlook remains attractive, citing three factors. First, Cabometyx, its main revenue driver, posted second-quarter revenue up 10.6% year over year to $628.7 million, and patent protection should keep generics out of the U.S. until at least 2030. Second, some analysts estimate zanzalintinib could generate $4.5 billion in U.S. sales by 2033, compared with $2.3 billion in revenue last year. Third, Exelixis has several other early-stage candidates and research collaborations in its pipeline.
- Booking vs. Chewy: Do Pet Treats or Plane Tickets Make for a Better Stock in 2026?
The article compares Booking Holdings (BKNG) and Chewy (CHWY) on 2025 results: Booking posted revenue of about $26.9 billion, up roughly 13.4%, with net income near $5.4 billion, while Chewy reported about $12.6 billion in revenue, up roughly 6.2%, but net income of only about $222.8 million. Chewy expanded into pet health with its acquisition of Modern Animal, bringing its veterinary clinic locations to 47. The article cites competition from Airbnb and major technology companies for Booking, and from Amazon for Chewy. On valuation, Booking is said to trade at a lower multiple of future earnings estimates, while Chewy trades at a much lower multiple of sales. The closing section highlights Chewy's Autoship program growing faster than overall sales.
- Is Berkshire Bending the Rules With Bending Spoons?
The Motley Fool Hidden Gems Investing podcast discusses Bank of America's earnings, including a $1.2 billion anti-money laundering penalty, with investment banking fees down 11% and the stock the worst performer among bank stocks after the report. The hosts compare the case with TD Bank's, which involved criminal conduct and an asset cap, noting Bank of America mainly failed to report some suspicious transactions in a timely manner despite a 2024 order, so an asset cap is considered unlikely unless the investigation reveals criminal activity. The episode also covers Fastenal's earnings, Berkshire Hathaway's added investment in Bending Spoons, and CoreWeave's debt falling into junk territory.
- Stock-Split Watch: Is Palantir Next?
Palantir stock has gained about 13.5%, and roughly 714% over the past five years, while the S&P 500 rose 70.5% over the same five-year period. The shares trade near $200, and the author says that level is not yet likely to prompt a split, though a move toward $500 that holds would make one more likely. Palantir has never split its stock in the roughly six years it has been publicly traded. In its Q2 report published in August, sales rose 93% year over year to $1.935 billion, and non-GAAP adjusted operating income reached $1.194 billion, a 62% margin. The author argues the company does not need a split to lift its valuation, and that its sales growth and margins could continue to support the stock's upward momentum.
- Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
CRISPR Therapeutics developed Casgevy, the first approved therapy using the CRISPR gene-editing technique in 2023, and shares its rights with Vertex Pharmaceuticals (VRTX). The article argues that the investigational CTX310, which targets high LDL cholesterol and triglycerides, could matter more to the company's future as a possible one-time option, since more than 40 million U.S. patients have high LDL or TG levels versus about 60,000 addressable patients for Casgevy. In a Phase 1a trial reported in August, the highest dose cut mean TG by 48% and mean LDL by 53% in patients with certain genetic conditions, and Phase 1b data are due in early November. Risks include clinical and regulatory setbacks, high prices and difficult administration. The author views the company as fairly attractive, but only for investors comfortable with significant risk and volatility.
- Amazon.com (AMZN) Cancels $427 Million Loudoun County Data Center Project
Amazon.com has dropped plans for a US$427 million data center complex in Loudoun County after sustained local opposition. According to local officials, part of the cancelled budget will go to new community investment initiatives in Northern Virginia. The article also cites Anthropic's report that cloud capacity for AI workloads is being rationed across large providers, including Amazon Web Services, because of supply constraints. Amazon's security teams are responding to the global PHP2Shell vulnerability, which targets PHP-based web servers and large-scale hosting environments. The article notes that Amazon continues heavy investment elsewhere, including a €16b program in Germany and work on small modular reactors.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.